AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $263.93. The company's market cap stands at 466.34B, with a P/E ratio of 74.65 and a dividend yield of 2.59%.
During the trading session on 2026-09-18, AbbVie(ABBV) shares reached a daily high of $266.34 and a low of $262.06. At a current price of $263.93, the stock is +0.7% higher than the low and still -0.9% under the high.
Trading activity shows a volume of 7.98M, compared to an average daily volume of 4.2M.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
ABBV News
Key Points AbbVie continues to diversify its revenue streams with successful expansions in immunology and aesthetics. Bristol-Myers Squibb maintains high net...
AbbVie (ABBV) presented new Vraylar data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie’s latest dry eye study compares its new ABBV-444 artificial tear against market stapl...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie (ABBV) is back in focus after fresh Phase 3 wins for etentamig in multiple myeloma and atogepant in menstrual migraine, reshaping how investors view its...
AbbVie (ABBV) company Allergan Aesthetics announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combinati...
AbbVie ABBV has significantly transformed its neuroscience portfolio over the years, evolving it from a relatively concentrated business initially anchored by V...
Key Points AbbVie has a fantastic dividend track record. The company's rock-solid business should help maintain its dividend growth streak for a long time. B...
Key Points Ken Griffin's Citadel increased its AbbVie stake by over 500% in the second quarter of 2026. AbbVie isn't cheap, but it has a strong drug portfolio...
Investing Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA A Roth IRA turns every dividend into a tax shield: qualified distribut...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.